Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMUNE NETWORK RESEARCH (VSE:IMM) -- Ignore unavailable to you. Want to Upgrade?

To: Al Collard who wrote (133)	1/21/2002 9:52:09 AM
From: John E.Quinn	Respond to of 134

Immune Network Announces Collaboration With Leading AIDS 03:28 EST Researcher Dr. Brian Conway At The University Of British Columbia NEWS RELEASE TRANSMITTED BY CCN NEWSWIRE FOR: IMMUNE NETWORK LTD. CDNX SYMBOL: IMM OTC Bulletin Board SYMBOL: IMMKF JANUARY 21, 2002 Immune Network Announces Collaboration With Leading AIDS Researcher Dr. Brian Conway At The University Of British Columbia VANCOUVER, CANADA--Immune Network Ltd. (OTCBB: IMMKF) announced today that it has signed a research agreement with Dr. Brian Conway, MDCM, FRCPC, of the University of British Columbia. This agreement will formalize the collaboration with the University, enhancing the development of the company's novel approaches to the treatment of chronic infections, such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV). A primary purpose of this collaboration is to learn more about 1F7 as a potential treatment for HIV and HCV. The 1F7 molecule is an Anti-Idiotypic Immunomodulatory Monoclonal Antibody ("AIMA"). Although research regarding AIMA technology has been published in peer-reviewed scientific journals for over a decade, its potential in the treatment of chronic and/or drug-resistant viral infections is only now being explored. This collaboration will also lead to the development of a research program to demonstrate the mechanism of action of 1F7 and to optimize the production of the antibody in preparation for future clinical trials. The collaboration will also provide support for research on the hNM01 monoclonal antibody, which had already begun phase I trials in the United States as a therapeutic vaccine against HIV. It is hoped that such trials could be re-initiated in this calendar year. Finally, the addition of other products to the portfolio will be considered, confirming Immune Network's commitment to the field of antiviral therapy. Dr. Brian Conway is a leading infectious disease scientist and clinician. Based in Vancouver, Canada, he combines a large tertiary care clinical practice in HIV with an ongoing University-based academic research program in this field. He has authored and conducted a number of clinical trials, with an emphasis on the development of models of care for intravenous drug users. He is the National Principal Clinical Investigator for Canadian HIV Trials Network Study 124 (CTN 124), an innovative approach to patients with acute HIV infection. He also holds a grant from the American National Institutes of Health (NIH) for related work in this field. Dr. Conway has published over 60 articles in peer-reviewed journals and is on the editorial board of both AIDS and the Journal of Acquired Immune Deficiency Syndromes. He is a member of the executive of the Canadian Association for HIV Research. "It is widely held that the next step forward in anti-HIV therapy will come from the field of immune intervention," said Dr. Conway, "Current antiretroviral medications will not lead to a cure for AIDS, and novel drugs that act against different targets in the viral life cycle are at least a few years away. Immune intervention, such as with drug candidates including 1F7 and hNM01, represents a novel and highly productive approach to the treatment of HIV infection and AIDS." Dr. Allen Bain, President and CEO of Immune Network, said, "I am very happy to formalize a significant collaborative relationship with Dr. Conway and the University of British Columbia. We expect Dr. Conway will play a pivotal role in the guidance of our antibody projects. His combined scientific and clinical competence will allow Immune Network to set and achieve new milestones for these projects in 2002 and onwards." The mission of Immune Network, "Biotech's Merchant Developer", is to acquire undervalued projects, to add value through R&D, and to divest prior to late stage product development through out-licensing or new company creation activities. On behalf of the Board of Directors Allen Bain, Ph.D., CEO "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward looking statements that are not historical facts and are subject to risks and uncertainties which could cause actual results to differ materially from those set forth in or implied herein. These risks are described in detail in the company's Securities and Exchange Commission filings. -30- FOR FURTHER INFORMATION PLEASE CONTACT: Immune Network Ltd. Investor Relations (604) 222-5541 or (Toll Free) 1-877-644-5541 ext. 466 (604) 222-5542 (FAX) Email info@immunenetwork.com Internet immunenetwork.com INDUSTRY: MTC SUBJECT: PRT -0-